Tango Therapeutics (TNGX) investor relations material

Company overview and leadership

• Focuses on PRMT5 pathway with several promising compounds and ongoing clinical trials.

• Employs about 160-170 people and is based in Boston.

• New CEO since January aims to transition the organization to late-stage, approval-ready status.

• No major strategic shifts expected with new leadership; main goal is vopimetostat approval.

PRMT5 pathway and clinical development

• PRMT5 inhibition targets cancers with MTAP deletion, potentially benefiting 60,000 US patients annually.

• Vopimetostat shows a favorable safety profile, with minimal toxicity and strong combinability.

• Monotherapy trial in pancreatic cancer showed a 25% response rate and 7.2-month PFS in second-line or higher settings.

• Additional data from non-small cell lung cancer and other indications expected later this year.

Combination strategies and collaborations

• Collaboration with Revolution Medicines combines vopimetostat with RAS inhibitors, showing synergistic preclinical data.

• Ongoing clinical trial since June last year with 30 patients enrolled across two combination arms.

• Combination aims for efficacy significantly above RAS inhibitor or vopimetostat monotherapy benchmarks.

• Combination is chemo-free, with minimal overlapping toxicity, potentially suitable for patients unable to tolerate chemotherapy.